Unreferenced stub auto yes date December 2009 Image Fibrinolysis.png thumb 400px Fibrinolysis A plasminogenactivator is a serine protease which converts plasminogen to plasmin, thus promoting fibrinolysis . Types include Tissue plasminogenactivator Urokinase It is inhibited by plasminogenactivatorinhibitor1 and plasminogenactivatorinhibitor 2 . Serine endopeptidases Antithrombotics Category Hematology DEFAULTSORT PlasminogenActivator blood drug stub pt Ativador do plasminog nio ... more details
PBB geneid 5054 Plasminogenactivatorinhibitor1 PAI 1 also known as endothelial plasminogenactivatorinhibitor or serpin E1 is a protein that in humans is encoded by the SERPINE1 gene . PAI 1 is a serine protease inhibitor serpin that functions as the principal inhibitor of tissue plasminogenactivator ... 14 title Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogenactivatorinhibitor1 design ... Mimuro J title Type 1plasminogenactivatorinhibitor its role in biological reactions journal ... BR title Plasminogenactivatorinhibitor1 physiological and pathophysiological roles journal News Physiol ... of plasminogenactivatorinhibitor type 1 PAI 1 with vitronectin Vn mapping the binding sites ... journal author Hertig A, Rondeau E title Plasminogenactivatorinhibitor type 1 the two faces of the same ..., Kluft C title Plasminogenactivatorinhibitor type 1 its plasma determinants and relation with cardiovascular ... journal author Hermans PW, Hazelzet JA title Plasminogenactivatorinhibitor type 1 gene polymorphism ... cgi bin merops.cgi?id I04.020 I04.020 MeshName PlasminogenActivatorInhibitor1 Coagulation Serpins ... PAI, plasminogenactivatorinhibitor 2 PAI 2 is secreted by the placenta and only present in significant .... PAI 1, however, is the main inhibitor of the plasminogen activators. Genetics The PAI 1 gene ... activatorinhibitor1, so it accelerates the development of atherosclerosis. Pharmacology Tiplaxtinin ... 4 author Elokdah H, Abou Gharbia M, Hennan JK, et al. ref Interactions Plasminogenactivatorinhibitor ... C S year 2001 month Sep. title Acute phase protein alpha 1 acid glycoprotein interacts with plasminogenactivatorinhibitor type 1 and stabilizes its inhibitory activity journal J. Biol. Chem. volume ... activatorinhibitor1 a common denominator in obesity, diabetes and cardiovascular disease journal ... es PAI 1 de Plasminogen Aktivator Inhibitor fr PAI 1 ... 1 inhibits the serine protease s tPA and uPA urokinase, and hence is an inhibitor of fibrinolysis ... more details
PBB geneid 5055 Plasminogenactivatorinhibitor 2 placental PAI is a coagulation factor that inactivates Tissue plasminogenactivator tPA and urokinase . It is present in most cells, especially monocytes ... internal signal peptide. Interactions Plasminogenactivatorinhibitor 2 SerpinB2 has been ... in immunity. Crit Rev Immunol. 2011 31 1 15 30. PMID 21395508. See also Plasminogenactivatorinhibitor1 Further reading refbegin 2 PBB Further reading citations cite journal author Rasmussen ... BS, Monroe MC, Bradshaw JD title Endotoxin induced production of plasminogenactivatorinhibitor by human ... Structure of the gene for human plasminogenactivatorinhibitor 2. The nearest mammalian homologue of chicken ... in Escherichia coli of a plasminogenactivatorinhibitor from human placenta. journal J. Biol ... plasminogenactivatorinhibitor. journal Proc. Natl. Acad. Sci. U.S.A. volume 85 issue 4 pages 985 ... RL, Hession C, et al. title Plasminogenactivatorinhibitor 2 regulation of gene transcription ... assignment, and homology to plasminogenactivatorinhibitor. journal J. Exp. Med. volume 166 issue ... JL, Bates EJ, Ferrante A, Antalis TM title Plasminogenactivatorinhibitor type 2 inhibits tumor ... cite journal author Mikus P, Urano T, Liljestr m P, Ny T title Plasminogenactivatorinhibitor type ... P, et al. title Plasminogenactivatorinhibitor type 2 an intracellular keratinocyte differentiation ... K, Kondo H, et al. title Microglia express the type 2 plasminogenactivatorinhibitor in the brain ... I04.007 MeshName PlasminogenActivatorInhibitor 2 Coagulation Serpins The PBB Controls template provides ... yes DEFAULTSORT PlasminogenActivatorInhibitor 2 Category Fibrinolytic system Category Serine protease ..., Wun TC, Behrendt N, et al. title Inhibition of receptor bound urokinase by plasminogenactivator inhibitors ... plasminogenactivator polarizes expression of the protease to the leading edge of migrating monocytes ... activatorinhibitor 2. Isolation and characterization of the promoter region of the gene ... more details
Complexes of tissue type plasminogenactivator and its serpin inhibitorplasminogenactivatorinhibitor type 1 are internalized by means of the low density lipoprotein receptor related protein alpha ...PBB geneid 5327 Tissue plasminogenactivator abbreviated tPA or PLAT is a protein involved in the breakdown ... to as recombinant tissue plasminogenactivator rtPA . Function Image Fibrinolysis.png left thumb ... or embolism . Tissue plasminogenactivator also plays a role in cell migration and tissue remodeling . Genetics Tissue plasminogenactivator is a protein encoded by the PLAT gene , which is located ... tissue plasminogenactivator for acute ischemic stroke in patients aged 90 years or older journal .... Interactions Tissue plasminogenactivator has been shown to Protein protein interaction interact ... Localization of the binding site of tissue type plasminogenactivator to fibrin journal J. Clin ... structure and function of tissue type plasminogenactivator journal Klin. Wochenschr. volume 66 Suppl ... type plasminogenactivator variants and crystal solution structures demarcate structural determinants ... function relationship at the lysine binding site and plasminogenactivator cleavage site journal ... role of the plasminogenactivator and matrix metalloproteinase systems journal Mol. Cell. Endocrinol ... cite journal doi 10.1042 BST0300183 author Teesalu T title Tissue plasminogenactivator as a key effector ... presenter.jhtml?identifier 4751 Tissue PlasminogenActivator from the American Heart ... no update citations yes DEFAULTSORT Tissue PlasminogenActivator Category Antithrombotic enzymes ... fa fr Activateur tissulaire du plasminog ne id Tissue plasminogenactivator nl Tissue plasminogenactivator ja pl Tkankowy aktywator plazminogenu pt Ativador ... that line the blood vessel s. As an enzyme , it catalysis catalyzes the conversion of plasminogen ..., tPA catalyzes the conversion of plasminogen into plasmin . It does so by cleaving the single ... more details
PBB geneid 5921 RAS p21 protein activator1 or RasGAP Ras GTPase activating protein , also known as RASA1 , is a 120 kDa cytosolic human protein that provides two principal activities Inactivation of Ras protein Ras from its active Guanosine triphosphate GTP bound form to its unactive Guanosine diphosphate GDP bound form by enhancing the endogenous GTPase activity of Ras, via its C terminal GAP domain Mitogenic signal transmission towards downstream interacting partners through its N terminal SH2 SH3 SH2 domains The PBB Summary template is automatically maintained by Protein Box Bot. See Template PBB Controls to Stop updates. PBB Summary section title summary text The protein encoded by this gene is located in the cytoplasm and is part of the GAP1 family of GTPase activating proteins. The gene product stimulates the GTPase activity of normal RAS p21 but not its oncogenic counterpart. Acting as a suppressor of RAS function, the protein enhances the weak intrinsic GTPase activity of RAS proteins resulting in the inactive GDP bound form of RAS, thereby allowing control of cellular proliferation and differentiation. Mutations leading to changes in the binding sites of either protein are associated ... protein activator GTPase activating protein 1 url http www.ncbi.nlm.nih.gov sites entrez?Db gene&Cmd ... domain s, a PH domain , and a GAP domain . Interactions RAS p21 protein activator1 has been shown ... FEBS Lett. volume 460 issue 1 pages 166 72 publisher location NETHERLANDS issn 0014 5793 pmid 10571081 ... journal Mol. Cell. Endocrinol. volume 183 issue 1 2 pages 113 21 publisher location Ireland issn ... quote doi 10.1016 S0303 7207 01 00587 1 ref ref name pmid9743338 cite journal last Jabado first N authorlink ... language format accessdate laysummary laysource laydate quote ref Insulin like growth factor 1 receptor ... C2 domain journal FEBS Lett. volume 469 issue 1 pages 88 92 publisher location NETHERLANDS issn 0014 ... forms a high molecular mass hetero oligomer with caveolin 1 journal J. Biol. Chem. volume 277 ... more details
Activator may mean Activator genetics , a DNA binding protein that regulates one or more genes by increasing the rate of transcription Activator proteomics , a type of effector that increases the rate of enzyme mediated reactions Activator phosphor , a type of dopant used in phosphor s and scintillator s Sega Activator , a motion sensing controller for the Sega Mega Drive Genesis Activator technique , a method of spinal adjustment disambig nl Activator sv Aktivator ... more details
. PBB geneid 575 Brain specific angiogenesis inhibitor1 is a protein that in humans is encoded ... specific angiogenesis inhibitor1 BAI1 journal Cytogenet Cell Genet volume 79 issue 1 2 pages ... receptor family, an inhibitor of angiogenesis and a growth suppressor of glioblastomas ref name entrez cite web title Entrez Gene BAI1 brain specific angiogenesis inhibitor1 url http www.ncbi.nlm.nih.gov ... specific angiogenesis inhibitor1 has been shown to Protein protein interaction interact with BAIAP3 ... inhibitor1 expression is inversely correlated with vascularity and distant metastasis of colorectal ... of mouse brain specific angiogenesis inhibitor1 BAI1 and phytanoyl CoA alpha hydroxylase associated protein 1, a novel BAI1 binding protein journal Brain Res. Mol. Brain Res. volume 87 issue ... inhibitor1 suppresses efficiently tumour angiogenesis journal Br. J. Cancer volume 86 issue 3 ... al. title Brain specific angiogenesis inhibitor1 BAI1 is expressed in human cerebral neuronal cells journal Neurosci. Res. volume 43 issue 1 pages 69 74 year 2002 pmid 12074842 doi 10.1016 S0168 0102 ... Extracellular fragment of brain specific angiogenesis inhibitor1 suppresses endothelial cell proliferation ... shown to be induced by wildtype p53. There are two other brain specific angiogenesis inhibitor genes ... Biochem. Biophys. Res. Commun. volume 251 issue 1 pages 158 65 publisher location UNITED STATES ... Jun. title Cloning and characterization of BAI associated protein 1 a PDZ domain containing protein ... VR, et al. title Release of an inhibitor of angiogenesis upon induction of wild type p53 expression ... specific p53 target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental ... of BAI associated protein 1 a PDZ domain containing protein that interacts with BAI1 journal .... Biophys. Res. Commun. volume 251 issue 1 pages 158 65 year 1998 pmid 9790924 doi 10.1006 bbrc.1998.9408 ... with the cytoplasmic domain of BAI1 journal Cytogenet. Cell Genet. volume 84 issue 1 2 pages 75 82 year ... more details
Plasminogen activators can refer to Tissue plasminogenactivator Urinary plasminogenactivator also known as urokinase disambig Short pages monitor This long comment was added to the page to prevent it being listed on Special Shortpages. It and the accompanying monitoring template were generated via Template Longcomment. Please do not remove the monitor template without removing the comment as well. ... more details
wiktionarypar inhibition inhibitor Something that restrains, blocks, or suppresses. Inhibitor or inhibition may refer to Corrosion inhibitor , a substance that decreases the rate of metal oxidation Enzyme inhibitor , a substance that binds to an enzyme and decreases the enzyme s activity Reuptake inhibitor , a substance that increases neurotransmission by blocking the reuptake of a neurotransmitter Inhibition of return , a feature of attention Inhibition Theory , a theory pertaining to the performance of a mental task Inhibitors Revelation Space , machines in Alastair Reynolds s Revelation Space novels Lateral inhibition , a mechanism by which neurons are able to determine the origin of a stimulus Memory inhibition , processes that suppress or interfere with specific memories Reaction inhibitor , a substance that prevents or decreases the rate of a chemical reaction Sexual inhibition , reservations relating to sexual practices Social inhibition , a conditioned fear reaction to social marginalization or isolation Inhibitions song Inhibitions , a 2008 single by Swedish band Alcazar Inhibitory postsynaptic potential , a synaptic potential that decreases the firing of a neuron See also Preservative , a substance that inhibits spoilage Embalming , the preservation of human remains Food preservation , the inhibition of microbial growth in food Nuclear poison , an inhibitor of nuclear reactions Disambig bs Inhibitor vor de Inhibition fr Inhibiteur it Inibizione nl Inhibitor tr Engelleyici ... more details
orphan date November 2009 Image SB activator front.jpg thumb Splint activator type K3F , frontal view... Image SB activator back.jpg thumb ...and back view The splint activator of Soulet Besombes is a removable appliance for the treatment of dental and jaw anomalies. It is basically a stylized activator , which is however not fitted individually, but is mass produced in various shapes and sizes. The device is also known as Position Trainer or Kaukraft Kiefer Former bite force jaw former, K3F . Design and operation The device is made from flexible material as one single piece. At its center, it is completely even and approximates the shape of an ideal dental arch. This flat part is surrounded by ramp shaped walls. The teeth of the upper and lower jaw bite into the space between these walls accordingly. Normally, there are no individual tooth slots, with the prominent exception of the Australian Myobrace design. The appliance sits passively between the upper and lower jaw, and does not exercise any force by itself to the teeth. When the patient bites together, the teeth standing out of line collide with ramp shaped walls and are moved into their correct position over time. This works due to the principle of the inclined plane and the spring force of the elastic deformation of the device. By biting more or less intensively, the patient can determine by himself how much force is applied. When the appliance is worn, the lower jaw is positioned into Angle class 1 relation towards the upper jaw. This is supposed to get the jaw muscles used to this position, and to let the patient learn the correct swallowing pattern. The teeth that in this jaw position do not reach the central plane ... today The splint activator is a rather exotic appliance, albeit in recent times, the Trainer for Kids ... patients of any age using the splint activator. External links http sodis apf.fr Societ por la distribution ... zahnklammern.de IzZ Info Basis und Initiative f r zwanglose Zahnspangen DEFAULTSORT Splint Activator ... more details
Image Phosphofructokinase 6PFK wpmp.png thumb right Bacillus stearothermophilus phosphofructokinase . PDB 6PFK . Enzyme activators are molecules that bind to enzyme s and increase their activity. These molecules are often involved in the allosteric regulation of enzymes in the control of metabolism . In opposition to coenzymes , enzyme activators are inorganic compound s, while both coenzyms and activators are Cofactor biochemistry cofactors . ref http www.elmhurst.edu chm vchembook 570enzymes.html ref An example of an enzyme activator working in this way is fructose 2,6 bisphosphate , which activates phosphofructokinase 1 and increases the rate of glycolysis in response to the hormone glucagon . ref cite journal author Kurland IJ, Pilkis SJ title Covalent control of 6 phosphofructo 2 kinase fructose 2,6 bisphosphatase insights into autoregulation of a bifunctional enzyme url http www.proteinscience.org cgi reprint 4 6 1023 journal Protein Sci. volume 4 issue 6 pages 1023 37 year 1995 pmid 7549867 date 06 01 1995 pmc 2143155 doi 10.1002 pro.5560040601 ref ref cite journal author Okar DA, Lange AJ title Fructose 2,6 bisphosphate and control of carbohydrate metabolism in eukaryotes journal Biofactors volume 10 issue 1 pages 1 14 year 1999 pmid 10475585 doi 10.1002 biof.5520100101 ref References reflist enzyme stub Category Enzyme kinetics nl Activator biochemie pt Ativador enzim tico sr Enzimski aktivator sv Enzymaktivator zh ... more details
Unreferenced date December 2009 An activator is a DNA binding protein that regulates one or more gene s by increasing the rate of transcription genetics transcription . The activator may increase transcription by virtue of a connected domain which assists in the formation of the RNA polymerase holoenzyme , or may operate through a Coactivator genetics coactivator . A coactivator binds the DNA binding activator and contains the domain assisting holoenzyme formation. A particular activator may bind one or more specific coactivators. Role in transcriptional regulation RNA polymerase RNAP is usually bound to the Promoter biology promoter region on the gene which creates a complex that sometimes undergoes a transition that allows Transcription genetics transcription to take place. An activator essentially recruits the RNAP to its promoter region, by binding to the activator binding site itself which serves as a liaison between the RNA polymers and the DNA. Sometimes, the activator is required for the RNA polymerase to change DNA conformation through allostery to initiate transcription. RNAP does not spontaneously transform into the open complex and requires the activator. Examples In the lac operon of the bacteria Escherichia coli , the Lac repressor is constitutively expressed and always bound to the Operon Operator operator region of the promoter, interfering with the ability of RNAP to bind to the promoter and transcribe the lac operon. In the presence of lactose , the repressor changes conformation and falls off the operator and RNAP is able to bind to the promoter. The catabolite activator protein CAP is an example of an activator for this operon, present in prokaryotic systems. Cyclic adenosine monophosphate cAMP is present in low levels of glucose, and binds to CAP which changes to an active conformation. Only then, can CAP act as an activator and help recruit RNAP to its ... terms DEFAULTSORT Activator Genetics Category Gene expression Category Proteins de Aktivator Genetik ... more details
Refimprove date December 2007 File Chiropractic Activator device.jpg thumb right Activator device The Activator Method Chiropractic Technique is a chiropractic treatment method and device created by Arlan Fuhr as an alternative to manual spinal manipulation manipulation of the spine or extremity joint manipulation joints . The device is categorized as a mechanical force manual assisted MFMA instrument which is generally regarded as a softer chiropractic treatment technique . Physical characteristics of the activator device The activator is a small handheld spring loaded instrument which delivers a small impulse to the spine. It was found to give off no more than 0.3 J of kinetic energy in a 3 millisecond pulse. The aim is to produce enough force to move the vertebrae but not enough to cause injury. ref name Fuhr2005 cite journal last Fuhr first Arlan W. authorlink coauthors J. Michael Menke year 2005 month February title Status of Activator Methods Chiropractic Technique, Theory, and Practice journal Journal of Manipulative and Physiological Therapeutics volume 28 issue 2 pages e1&ndash e20 id url http linkinghub.elsevier.com retrieve pii S0161475405000023 accessdate 2008 08 18 quote doi 10.1016 j.jmpt.2005.01.001 pmid 15800504 ref Activator method chiropractic technique The activator method chiropractic technique AMCT involves having the patient lie in a prone position and comparing the functional leg lengths. Often one leg will seem to be slightly shorter than the other. The chiropractor then carries out a series of muscle tests such as having the patient move their arms in a certain ... name PBS activator http www.pbs.org saf 1210 features spine.htm Keeping Your Spine In Line , http ... . Video discusses Activator and leg length ref Fuhr claims that properly trained doctors show good interexaminer ... chapter 10.pdf format PDF accessdate 2008 08 25 isbn 1 884457 05 3 ref The majority of U.S. chiropractic ... trials, but there are still unanswered questions. A few studies suggest that the activator may be as effective ... more details
Mechanisms of Mutagenesis volume 571 issue 1 2 pages 121 132 year 2005 pmid 15748643 doi 10.1016 ... . The tanning activator coumarin is known to induce thymine dimers cyclobutane pyrimidine ... Sun, Chung Ming title Recent Advances in Coumarins and 1 Azacoumarins as Versatile Biodynamic Agents ... more details
unreferenced date March 2010 In phosphor s and scintillator s, the activator is the element added as dopant to the crystal of the material to create desired type of nonhomogeneities. In luminescence , only a small fraction of atoms, called emission centers or luminescence centers , emit light. In inorganic phosphors, these inhomogeneities in the crystal structure are created usually by addition of a trace amount of dopant s, impurities called activators . In rare cases dislocation s or other crystal defect s can play the role of the impurity. The wavelength emitted by the emission center is dependent on the atom itself, its electronic configuration , and on the surrounding crystal structure. The activators prolong the emission time afterglow . In turn, other materials such as nickel can be used to quench the afterglow and shorten the decay part of the phosphor emission characteristics. The electronic configuration of the activator is depending on its oxidation state and is crucial for the light emission. Oxidation of the activator is one of the common mechanisms of phosphor degradation. The distribution of the activator in the crystal is also of high importance. Diffusion of the ions can cause depletion of the crystal from the activators with resulting loss of efficiency. This is another mechanism of phosphor degradation. The scintillation process in inorganic materials is due to the electronic band structure found in the crystal s. An incoming particle can excite an electron from the valence band to either the conduction band or the exciton band located just below the conduction band and separated from the valence band by an energy gap see picture . This leaves an associated electron hole hole behind, in the valence band. Impurities create electronic levels in the forbidden ... scintillation light fast component . In case of inorganic scintillator s, the activator impurities ... , again results in light emission slow component . The activator is the main factor determining ... more details
are defined by the inhibitor concentration and its two dissociation constants math alpha 1 frac I K i math math alpha prime 1 frac I K i prime . math Thus, in the presence of the inhibitor, the enzyme ... File Ritonavir.png thumb 170px right Peptide based HIV 1 protease inhibitor ritonavir As enzymes ... thumb 200px left Nonpeptidic HIV 1 protease inhibitor tipranavir However, not all inhibitors ... glyphosate is an inhibitor of 3 phosphoshikimate 1 carboxyvinyltransferase , ref cite journal ... with the protease inhibitor ritonavir . The structure of the protease is shown by the red, blue and yellow ribbons. The inhibitor is shown as the smaller ball and stick structure near the centre. Created from PDB http www.rcsb.org pdb explore.do?structureId 1HXW 1HXW . An enzyme inhibitor is a molecule ... enzyme activator s bind to enzymes and increase their enzyme assay enzymatic activity .... The binding of an inhibitor can stop a substrate biochemistry substrate from entering the enzyme s active site and or hinder the enzyme from catalysis catalysing its reaction. Inhibitor binding ... and pharmacology . A medicinal enzyme inhibitor is often judged by its specificity tests specificity ... s a well characterised example is the ribonuclease inhibitor , which binds to ribonuclease ... placental ribonuclease with placental ribonuclease inhibitor journal Biochemistry volume 30 ... bond s, hydrophobic interaction s and ionic bond s. Multiple weak bonds between the inhibitor and the active ... inhibitor.svg thumb 150px left Competitive inhibition substrate S and inhibitor I compete for the active ... to the effect of varying the concentration of the enzyme s substrate on the inhibitor. ref Berg J., Tymoczko ... , the substrate and inhibitor cannot bind to the enzyme at the same time, as shown in the figure on the left. This usually results from the inhibitor having an affinity for the active site of an enzyme where the substrate also binds the substrate and inhibitor compete for access to the enzyme s active ... more details
Protease inhibitor can refer to Protease inhibitor pharmacology a class of medication that inhibits viral protease Protease inhibitor biology molecules that inhibit proteases disambig ... more details
Unreferenced stub auto yes date December 2009 Image Uncompetitive inhibition.png thumb right 250px Lineweaver Burk plot of uncompetitive enzyme inhibition. Uncompetitive inhibition , also known as anti competitive inhibition , takes place when an enzyme inhibitor binds only to the complex formed between the enzyme and the substrate biochemistry substrate the E S complex . The initial theory was developed by molecular theorist Jude Jocham, and was thought to be imaginary. Mechanism This reduction in the effective concentration to the E S complex increases the enzyme s apparent affinity for the substrate through Le Chatelier s principle K sub m sub is lowered and decreases the maximum enzyme activity V sub max sub , as it takes longer for the substrate or product to leave the active site . Uncompetitive inhibition works best when substrate concentration is high. An uncompetitive inhibitor need not resemble the substrate of the reaction it is inhibiting. Equation math 1 v frac K m V max S frac 1 I K i V max math The Lineweaver Burk plot Lineweaver Burk equation for an uncompetitive inhibitor produces a line parallel to the original enzyme substrate plot, but with a lower y intercept due to the inhibition term math I K i math . Enzyme inhibition DEFAULTSORT Uncompetitive Inhibitor Category Enzyme kinetics Category Enzyme inhibitors Enzyme stub ... more details
Image Bortezomib.svg 200px thumb Structural formula Chemical structure of bortezomib , the first proteasome inhibitor approved for use. Proteasome inhibitors are drugs that block the action of proteasome s, cellular complexes that break down protein s, like the p53 protein. Proteasome inhibitors are being studied in the treatment of cancer . Examples In 2003, bortezomib was the first proteasome inhibitor to be approved for use in the U.S. Disulfiram has been proposed as another proteasome inhibitor. ref cite journal author L vborg H, Oberg F, Rickardson L, Gullbo J, Nygren P, Larsson R title Inhibition of proteasome activity, nuclear factor KappaB translocation and cell survival by the antialcoholism drug disulfiram journal International Journal of Cancer volume 118 issue 6 pages 1577 80 year 2006 month March pmid 16206267 doi 10.1002 ijc.21534 ref ref cite journal author Wickstr m M, Danielsson K, Rickardson L, et al. title Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients journal Biochemical Pharmacology volume 73 issue 1 pages 25 33 year 2007 month January pmid 17026967 doi 10.1016 j.bcp.2006.08.016 ref ref cite journal author Cvek B, Dvorak Z title The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? journal Drug Discovery Today volume 13 issue 15 16 pages 716 22 year 2008 month August pmid 18579431 doi 10.1016 j.drudis.2008.05.003 ref Epigallocatechin 3 gallate has also been proposed. ref name pmid17544279 cite journal author Osanai K, Landis Piwowar KR, Dou QP, Chan TH title A para amino substituent on the D ring of green tea polyphenol epigallocatechin 3 gallate as a novel proteasome inhibitor and cancer cell apoptosis inducer journal Bioorg. Med. Chem. volume 15 issue 15 pages 5076 82 year 2007 month August pmid 17544279 pmc 2963865 doi 10.1016 j.bmc.2007.05.041 url http linkinghub.elsevier.com retrieve pii S0968 0896 07 004 ... more details
competitive inhibitor of phosphodiesterases 1 5, displaced 3 H rolipram from high affinity rolipram ...Image Piclamilast.png thumb Piclamilast , a common PDE4 inhibitor A phosphodiesterase type 4 inhibitor , commonly referred to as a PDE4 inhibitor , is a drug used to block the degradative action of phosphodiesterase 4 PDE4 on cyclic adenosine monophosphate cAMP . It is a member of the larger family of Phosphodiesterase inhibitor PDE inhibitors . The PDE4 family of enzymes are the most prevalent PDE in immune cells . They are predominantly responsible for hydrolyzing cAMP within both immune cells and cells in the central nervous system. ref cite journal doi 10.1038 bjp.2008.307 title PDE4 inhibitors current status journal British Journal of Pharmacology year 2008 first D last Spina volume 155 ... Parkinson s ref name U. S. ARMY MEDICAL RESEARCH 2005 11 cite web url http handle.dtic.mil 100.2 ... medications journal Neuroscience. year 2004 pages 101 7 volume 129 issue 1 pmid 15489033 ... Rolipram A specific phosphodiesterase 4 inhibitor with potential antipsychotic activity journal Neuroscience. year 2006 pages 239 246 volume 144 issue 1 pmid 17081698 ref improved long term memory, ref ... Rolipram, a type IV specific phosphodiesterase inhibitor, facilitates the establishment of long lasting ... implicated side effects of PDE4 inhibitors. Examples anchor PDA4 inhibitor Mesembrine , an alkaloid ..., and so acts as a selective PDE4 inhibitor or a non selective phosphodiesterase inhibitor, depending on the dose. Piclamilast , a more potent inhibitor than rolipram. ref name Piclamilast Walther ... ref Luteolin , supplement extracted from peanuts that also possesses IGF 1 properties. ref ... 2009 pages 269 75 volume 627 issue 1 3 pmid 19853596 doi 10.1016 j.ejphar.2009.10.031 ref Roflumilast ... nucleotide phosphodiesterase type 4 inhibitor. British Journal of Pharmacology, 123 1047 1054. Mode ... Reflist Phosphodiesterase inhibitors DEFAULTSORT Pde4 Inhibitor Category PDE4 inhibitors de ... more details
ALK inhibitors are potential anti cancer drug s that act on tumours with variations of anaplastic lymphoma kinase ALK such as an EML4 Anaplastic lymphoma kinase ALK translocation . ref cite web url http www.medscape.com viewarticle 715243 title ALK Inhibitors Possible New Treatment for Lung Cancer author Nelsen year 2010 ref EML4 ALK About 7 of Non small cell lung carcinoma s NSCLC have EML4 ALK translocations. ref name Farmer2010 Crizotinib is in clinical trials for NSCLC. ref name Farmer2010 cite web url http www.genengnews.com gen articles treatment paradigm shifting for nsclc 3423?page 1 title Non Small Cell Lung Cancer Standards of Care Challenged by a Cornucopia of New Drugs author Farmer year 2010 ref with good results in phase II. ref cite web url http www.medscape.com viewarticle 723075 title Crizotinib in ALK NSCLC Response Rate Unprecedented author Chustecka year 2010 ref FDA approved in Aug 2011. AP26113 is at the preclinical stage. ref cite web url http www.news medical.net news 20100421 ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting.aspx title ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting year 2010 ref NPM ALK NPM ALK is a different variation fusion of Anaplastic lymphoma kinase ALK that drives anaplastic large cell lymphoma s ALCLs and is the target of other ALK inhibitors. ref cite web url http www.pnas.org content 104 1 270.short title Identification of NVP TAE684, a potent, selective, and efficacious inhibitor of NPM ALK year 2007 author Galkin et al ref ref http www.axonmedchem.com product 1416tae684.html ref References reflist Category Experimental cancer drugs antineoplastic drug stub ... more details
Image Escitalopram structure.svg thumb right 160px Escitalopram , a selective serotonin reuptake inhibitor SSRI used as an antidepressant. A reuptake inhibitor RI , also known as a transporter blocker ... of psychopharmacology. journal Br J Pharmacol. volume 147 issue 1 pages S82 88 year 2006 ..., Rickels K title The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety ... Lett. volume 230 issue 1 pages 21 4 year 1997 pmid 9259454 ref ref name pmid16770320 cite journal ..., Giagnoni G title AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine ... of the adenosine reuptake inhibitor soluflazine on synaptic potentials and population hypoxic ... Tiagabine.svg thumb right 160px Tiagabine , a selective GABA reuptake inhibitor used as an anticonvulsant ... transporters. journal J Pharmacol Exp Ther. volume 307 issue 1 pages 34 41 year 2003 ... MP, Rothman RB. title 3H 1 2 2 thienyl cyclohexyl piperidine labels two high affinity binding sites ... ligand with high affinity and selectivity for the MK801 insensitive 3H 11 2 thienyl cyclohexyl piperidine binding site PCP site 2 of guinea pig brain. journal Synapse. volume 16 issue 1 pages 59 65 ... 0362 94 90022 1 author Rothman RB. title PCP site 2 a high affinity MK 801 insensitive phencyclidine ... 1 pages 385 395 year 1995 pmid 7616423 ref Benztropine , fluoxetine , mazindol , and vanoxerine ... analog 125I RTI 55. journal J Pharmacol Exp Ther. volume 270 issue 1 pages 296 309 year 1994 pmid ... of the selective serotonin reuptake inhibitor s SSRIs such as fluoxetine and the dextro enantiomer of citalopram appear to be allosteric serotonin reuptake inhibitor s. ref name pmid15695064 cite journal ... inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other .... journal Int J Neuropsychopharmacol. volume 10 issue 1 pages 31 40 year 2007 pmid 16448580 doi 10.1017 ... inhibitor . Notably, this allosteric site may be directly related to the above mentioned phencyclidine ... more details
about the medical therapy the cell cycle protein Cyclin dependent kinase inhibitor protein A CDK Cyclin dependent kinase inhibitor is a chemical that inhibits the function of Cyclin dependent kinase CDK s. It is used to treat cancer s by preventing overproliferation of cancer Cell biology cell s. Although there is no approved anti cancer drugs that target CDKs yet, several compounds are on clinical trials now 2009 . CDKs as cancer target In many human cancers, CDKs are overactive or CDK inhibiting proteins are not functional ref Malumbres, M., and Barbacid, M. 2001 . To cycle or not to cycle a critical decision in cancer. Nature reviews 1, 222 231. ref ref Malumbres, M., and Barbacid, M. 2009 . Cell cycle, CDKs and cancer a changing paradigm. Nature reviews 9, 153 166. ref . Therefore, it is rational to target CDK function to prevent unregulated proliferation of cancer cells. However, the validity of CDK as a cancer target should be carefully assessed because genetic studies have revealed that knockout of one specific type of CDK often does not affect proliferation of cells or has an effect only in specific Tissue biology tissue types. For example, most adult cells in mice proliferate normally even without both CDK4 and CDK2 ref Barriere, C., Santamaria, D., Cerqueira, A., Galan, J., Martin, A., Ortega, S., Malumbres, M., Dubus, P., and Barbacid, M. 2007 . Mice thrive without Cdk4 and Cdk2. Molecular oncology 1, 72 83. ref . Furthermore, specific CDKs are only active in certain periods of the cell cycle. Therefore, the pharmacokinetics and dosing schedule of the candidate compound must be carefully evaulated to maintain active concentration of the drug throughout the entire cell cycle ref Malumbres, M., Pevarello, P., Barbacid, M., and Bischoff, J.R. 2008 . CDK inhibitors ... such as VEGFR or PDGFR CDK inhibitors on clinical trials There are more than 10 CDK inhibitor compounds ... DEFAULTSORT Cdk Inhibitor Category Protein kinase inhibitors medicine stub de CDK Inhibitor 2A ... more details
Encyclopedia
top
